Latest topics referred to NICE: July 2012
Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence (NICE).
These were referred in July, to begin the process of developing guidance for each topic.
Technology appraisals
The following technology appraisals have been referred to NICE.
- To appraise the clinical and cost effectiveness of mirabegron within its licensed indication for the treatment of symptoms associated with overactive bladder.
- To appraise the clinical and cost effectiveness of pertuzumab in combination with trastuzumab and docetaxel within its licensed indication for the treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic or locally recurrent unresectable breast cancer, which has not been previously treated, or has relapsed after adjuvant therapy.
- To appraise the clinical and cost effectiveness of everolimus in combination with an aromatase inhibitor within its licensed indication for the treatment of human epidermal growth factor 2 (HER2) negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy.
- To appraise the clinical and cost effectiveness of phentermine with topiramate within its licensed indication for the treatment of adults who are obese or who are overweight and have weight-related co-morbidities.
- To appraise the clinical and cost effectiveness of tadalafil within its licensed indication for the treatment of symptoms associated with benign prostatic hyperplasia.
Read about NICE technology appraisals on the NICE website.
About NICE referrals
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.
Department of Health ministers refer topics to NICE and NICE schedules these topics into its work programme, to begin the process of developing guidance for each topic.
Depending on the type of guidance and its complexity, this can take between 6 months and 2 years.
NICE guidance includes technology appraisals, clinical guidelines, public health guidelines and quality standards.
Find out more about NICE guidance on the NICE website.